取健康“O”型供血者的PBMC经PHA预刺激后制成PHA-LAK,其表型以CD3~+、CD8~+为主,IL-2R表达水平、增殖能力、体外存活时间及细胞毒活性等均明显优于常规LAK。用该PHA-LAK(PHA预刺激的LAK细胞)与rIL-2(TGP-3,日本,武田)治疗60例实体瘤患者(肾癌24例,肝癌、恶性淋巴瘤、结肠癌各5例,肺癌12例,其它恶性肿瘤9例)。Ⅰ、Ⅱ期临床试验结果表明,本PHA-LAK/IL-2疗法毒副作用甚轻或无,对肾癌、肝癌、恶性淋巴瘤的近期疗效较好,从而为肿瘤的继承性细胞免疫治疗开拓了新路。

PHA-LAK cells were prepared from PBMC of healthy "O"-blood type donor (Primed with PHA for 48 hours then cultured in the presence of rIL - 2), showing predominantly CD3 CD8 in phenotype. The expression level of IL - 2R of PHA - LAK was higher than that of conventional LAK (C - LAK, induced by rIL - 2 only), andon the proliferative ability, in vitro survival time and cytotoxicity PHA-LAK exhibited some advantages thanC-LAK. 60 cases of various solid tumor patients (renal cell carcinoma 24 cases, liver cancer, malignant lyrnphoma,colon carcinoma 5 cases each, lung cancer 12 cases and other miscellaneous cancer 9 cases) were treated with PHA - LAK in combination with rIL - 2 (TGP - 3, Takeda, Japan) . The results of phase I and Phase II clinical trials indicated that PHA - LAK/IL - 2 therapy was relatively safe (showing very mild or no side effect) and effective (especially against renal cell carcinoma, malignant lymphoma and liver cancer) . Thus PHA-LAK/IL-2 might provide a new therapeutic approach to cancer adoptive immunotherapy.

“八、五”国家攻关专题(859140208)的组成部分